C. Fritz

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.

Matthias Schneider, G. Burmester, A. Krause, 2011, Rheumatology.

Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

Andreas Krause, H. Zeidler, G. Burmester, 2007, Annals of the rheumatic diseases.

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years

J. Braun, J. Listing, J. Sieper, 2013, Arthritis Research & Therapy.